Gilead shares up approximately 30% this year following consecutive FDA approvals
GILD Gilead Sciences Inc
$156.19 -0.75%
View chart & analysis → - 1Gilead Sciences (GILD) has risen nearly 30% this year after receiving approvals for the new HIV drug Bixlenvo and the hepatitis treatment Hepcludex.
- 2Second-quarter revenue increased 10% to $7.8 billion, while HIV product revenue grew 12% to $5.7 billion.
- 3Trodelvy expanded its indications as a first-line treatment, and the original text expects new approvals to offset the decline in Veklury sales.
So what's the key point?
Gilead has received consecutive approvals for new drugs. Second-quarter revenue increased 10% and the stock price has risen nearly 30% this year.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.